Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium, oxymetazoline, and pseudoephedrine for symptom relief in acute common cold
ACTRN12606000482561Phase 3Completed
- Sponsor
- Common Cold Unit
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of ipratropium bromide, oxymetazoline and pseudoephedrine in nasopharyngitis (6 arms), sponsored by Common Cold Unit. Primary endpoint: Relief of nasal congestion over 48 hours. Started May 2004; status: completed.
02
Drugs
ipratropium bromideoxymetazolinepseudoephedrine
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ACTRN12606000482561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000482561.